Biocure Technology (XCNQ:CURE) 3-Year FCF Growth Rate : 46.40% (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Biocure Technology 3-Year FCF Growth Rate?

Biocure Technology's Free Cash Flow per Share for the three months ended in Mar. 2024 was C$0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 46.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 42.60% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -24.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Biocure Technology was 55.70% per year. The lowest was -236.20% per year. And the median was 33.50% per year.

Competitive Comparison of Biocure Technology's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Biocure Technology's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocure Technology's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocure Technology's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Biocure Technology's 3-Year FCF Growth Rate falls into.

Biocure Technology 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Biocure Technology (XCNQ:CURE) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Biocure Technology 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Biocure Technology's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocure Technology (XCNQ:CURE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocure Technology Inc (XCNQ:CURE) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 2E9

Website

https://www.biocuretech.com

Biocure Technology Inc is a South Korean-based Bio-Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. It is in the process of preclinical trials of five majorly biosimilar products in South Korea, including Interferon Beta 1b, PEGFilgrastim, and Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes.